Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors-Reference-Cited by-同舟云学术

Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors

Published:2012-01 Issue:1 Volume:3 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Yu Wenyu,Chory Emma J.,Wernimont Amy K.,Tempel Wolfram,Scopton Alex,Federation Alexander,Marineau Jason J.,Qi Jun,Barsyte-Lovejoy Dalia,Yi Joanna,Marcellus Richard,Iacob Roxana E.,Engen John R.,Griffin Carly,Aman Ahmed,Wienholds Erno,Li Fengling,Pineda Javier,Estiu Guillermina,Shatseva Tatiana,Hajian Taraneh,Al-awar Rima,Dick John E.,Vedadi Masoud,Brown Peter J.,Arrowsmith Cheryl H.,Bradner James E.,Schapira Matthieu

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms2304.pdf

Reference28 articles.

1. Arrowsmith C. H., Bountra C., Fish P. V., Lee K. & Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384–400 (2012).

2. Chi P., Allis C. D. & Wang G. G. Covalent histone modifications–miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10, 457–469 (2010).

3. Copeland R. A., Solomon M. E. & Richon V. M. Protein methyltransferases as a target class for drug discovery. Nat. Rev. Drug Discov. 8, 724–732 (2009).

4. Campagna-Slater V. et al. Structural chemistry of the histone methyltransferases cofactor binding site. J. Chem. Inf. Model 51, 612–623 (2011).

5. Richon V. M. et al. Chemogenetic analysis of human protein methyltransferases. Chem. Biol. Drug Des. 78, 199–210 (2011).

Cited by 243 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Novel Non-nucleoside DOT1L^R231Q Inhibitors with Improved Pharmacokinetic Properties and Anti-lung Cancer Efficacy;Journal of Medicinal Chemistry;2024-09-10

2. Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HATs as anti-leukemia agents;Bioorganic Chemistry;2024-09

3. Discovery of first-in-class DOT1L inhibitors against the R231Q gain-of-function mutation in the catalytic domain with therapeutic potential of lung cancer;Acta Pharmaceutica Sinica B;2024-08

4. Tracking DOT1L methyltransferase activity by stable isotope labelling using a selective synthetic co-factor;Communications Chemistry;2024-06-27

5. TET2 Deficiency Increases the Competitive Advantage of Hematopoietic Stem Cells through Upregulation of Thrombopoietin Receptor Signaling;2024-03-25